Stock Markets May 19, 2026 07:13 PM

International Firms Renew Interest in Hong Kong Listings as IPO Activity Strengthens

Exchange executive says about 10 non-China companies have filed this year as HKEX seeks to broaden its international appeal

By Avery Klein

Hong Kong is drawing renewed interest from overseas issuers as a rebound in initial public offering activity on the mainland and in the city coincides with greater foreign capital flows. An HKEX executive said roughly 10 companies from markets such as Indonesia, South Korea and Singapore have filed for listings in Hong Kong this year, with a wider pipeline under consideration.

International Firms Renew Interest in Hong Kong Listings as IPO Activity Strengthens

Key Points

  • About 10 foreign firms from markets such as Indonesia, South Korea and Singapore have filed for Hong Kong listings this year, with more exploring options.
  • Domestic issuance remains dominant - 110 Chinese and Hong Kong companies raised $36.4 billion in 2025 - but international filings could make 2026 the best year for foreign debuts since at least 2020.
  • The prospective international issuers span technology, consumer and financial sectors and include first-time IPOs, concurrent dual listings and sequential dual listings.

Hong Kong’s equity market is seeing a lift in interest from non-domestic issuers amid stronger IPO momentum and rising cross-border investment flows. Johnson Chui, head of global issuer services at Hong Kong Exchanges and Clearing Ltd (HKEX), said this year about 10 firms based in countries including Indonesia, South Korea and Singapore have submitted filings for listings in the city, and additional international companies are exploring options.

Although that foreign interest is measured against heavy domestic issuance - 110 Chinese and Hong Kong companies raised $36.4 billion in 2025, according to LSEG data - the arrival of roughly 10 international filers would represent Hong Kong’s strongest showing for non-domestic debuts since at least 2020. The prospective foreign issuers span technology, consumer and financial sectors, Chui said.

The transactions in the pipeline cover a range of listing approaches, including first-time initial public offerings, concurrent dual listings and sequential dual listings, Chui added. "We feel that this is the start of a structural change of the next phase of international companies listing in Hong Kong," he said, noting that the exchange’s pull has broadened beyond companies with direct business exposure to Greater China.

"The nexus is broadening," Chui said. "In the past it was more: do you have business exposure in Greater China? But now, there are very successful examples for companies that have no business at all in this part of the world."

HKEX has been the primary destination for Chinese issuers seeking offshore capital and was the world’s busiest market for IPOs last year, with $37.4 billion raised through 115 deals, according to LSEG data.

Despite the broader ambition to attract large overseas listings having limited success to date, HKEX is renewing its outreach at a time when mainland China and Hong Kong equity markets are enjoying strong momentum. That environment, together with increased foreign capital flows, underpins the exchange’s effort to diversify its issuer base.

Market watchers say a potential blockbuster listing could boost the exchange’s credibility with international issuers. Swiss-based seeds and agrochemicals company Syngenta Group plans a listing of up to $10 billion in the second half of this year, a development reported in February, which market participants expect would strengthen HKEX’s ability to attract big-ticket deals.

Chui declined to name specific foreign IPO hopefuls, but separate sources identified international biotech companies Engine Biosciences from Singapore and U.S.-based NiKang Therapeutics as among firms that have considered possible listings in Hong Kong. The discussions remain preliminary and plans could change, the sources said. They spoke on condition of anonymity. Engine Biosciences declined to comment, while NiKang did not respond to requests for comment.

Some issuers have been more forthcoming about Hong Kong as an option. Teleport, a Malaysian logistics company, told investors that Hong Kong is among the venues it is evaluating. "Our long-term roadmap includes a public listing," CEO Pete Chareonwongsak said. "We are keeping our options open."

LSEG data compiled on May 4 indicated a potential pipeline of 12 foreign companies for Hong Kong IPOs in 2026, including U.S. blockchain infrastructure firm Blockdaemon, Malaysian group Capital A which spans branding to logistics, and British biopharmaceutical company Allergy Therapeutics. HKEX said seven international companies listed in Hong Kong in 2025.

Since 2000, LSEG data show foreign companies have raised about $22 billion across 156 deals in Hong Kong, a modest share of the market’s total issuance. The present wave of interest differs from a previous international push roughly 15 years ago, which was driven by consumer names such as Prada and Samsonite; the current pipeline is more diverse across sectors, geographies and listing structures.

Industry participants highlight several practical attractions. Kenneth Chow, Citigroup’s Asia head of equity capital markets, said Hong Kong provides access to "the widest possible universe" of investors, encompassing global funds, hedge funds, Chinese institutions and retail buyers. From a sector angle, advisors note that some mining companies are attracted by China’s demand for strategic minerals, while others point to the development of market infrastructure.

George Wu, a partner at DLA Piper, said mining firms are being drawn by China-driven demand for strategic minerals. Jean Thio, a partner for capital markets at Clifford Chance, said Hong Kong has built a system that rivals alternative venues in assembling listed companies, analyst coverage and market comparables in industries such as biotech and AI. "We feel Hong Kong is the listing venue of choice for all international companies and issuers with an Asian nexus," Chui said.


Bottom line: HKEX is seeing renewed international interest as IPO markets heat up, with a modest but notable number of foreign firms filing this year and a broader 2026 pipeline under consideration. The mix of sectors and listing structures suggests a different profile from earlier waves of foreign listings, even as domestic issuance continues to dominate the market.

Risks

  • Plans by international firms to list in Hong Kong are preliminary and could change, exemplified by discussions around Engine Biosciences and NiKang Therapeutics where plans remain unsettled - this creates uncertainty for the exchange and sectors expecting new listings.
  • Efforts to attract large overseas listings have had limited success so far; reliance on a small number of potential big-ticket deals to shift the exchange’s profile poses execution risk for HKEX and related market participants.
  • Foreign listings historically account for a small share of total capital raised in Hong Kong (about $22 billion across 156 deals since 2000), indicating that enlarging the international issuer base may be a gradual process with uncertain near-term impact on overall market composition.

More from Stock Markets

UK to Strengthen Powers to Curb Crisis Price Hikes May 19, 2026 Lincoln International Prices IPO at $20 Per Share, Setting Stage for NYSE Debut May 19, 2026 Senators Question Transportation Secretary Over Corporate-Funded Family Road Trip May 19, 2026 Stellantis to Produce Voyah Electric Vehicle for Dongfeng at Rennes Plant, Sources Say May 19, 2026 Mexican Stocks Close Higher; S&P/BMV IPC Advances 0.22% May 19, 2026